CYTOGEN ANNOUNCES SUCCESSION PLAN 
        AS PART OF LONG TERM CORPORATE STRATEGY 

PRINCETON, NJ, November 13, 1997 -- CYTOGEN Corporation
(NASDAQ:CYTO)today announced, consistent with its long term
corporate strategy,plans for management succession. Chairman,
President and Chief Executive Officer Thomas J. McKearn, M.D.,
Ph. D., has advised the Board of Directors that he desires to
step down from those positions and return to a scientific role in
the Company, a position similar to that which he held for many
years prior to assuming the responsibility for CYTOGEN's overall
leadership.  The Company plans to recruit new chief executive
leadership. 

Dr. McKearn will remain in his current role pending completion of
the Board's search for a new Chief Executive Officer.  The
Company also indicated that no time frame could be given for the
change, which would depend on identification of the right
candidate.  The Board has accepted Dr. McKearn's request and
believes there is considerable merit in a newly defined
scientific role, but indicated that any final decision could only
be determined at the time a new Chief Executive Officer is
appointed. 

"In recent years, CYTOGEN has matured from being principally a
 research and development company to a commercial concern with
three marketed products and other products in late stages of
clinical development,"  said Dr. McKearn.  "Thus, the time and
circumstances are appropriate to recruit a chief executive with
more substantial industry experience on business and financial
matters who can guide CYTOGEN through its next phase of growth."  


"The clinical and regulatory functions will continue to occupy
critical and increasingly important roles in bringing new
products to the market,"  said Dr. McKearn.  "In addition, the
need exists to bring even more focus and resources to CYTOGEN's
Genetic Diversity Library technology, whose broad commercial
potential has given birth to several of the Company's strategic
business units and offers still more opportunities for the
future.  I believe that my most significant contribution to
CYTOGEN can be made by concentrating my efforts on these
technical and scientific activities.  I look forward to being
able to define with a new Chief Executive Officer how I can best
serve the needs of the Company." 

Dr. McKearn originally joined CYTOGEN in 1981 at the Company's
founding, and became its Chief Executive Officer in 1995 and
Chairman in 1996.

CYTOGEN is a biopharmaceutical company engaged in the
development, manufacture and commercialization of products for
targeted delivery of diagnostic and therapeutic substances
directly to disease sites.  CYTOGEN has demonstrated its ability
to develop new technology from early discovery through clinical
development, regulatory approval and commercial-scale biologic
manufacturing.

Information in this press release which is not historical is
forward looking, and subject to risks and uncertainties.  Actual
results or events may differ materially for various reasons,
including lack of commercial acceptance of the Company's
products, the uncertainties inherent in locating a qualified
successor or in determining the future management structure of
the Company, and other risks described in the Company's filings
with the Securities and Exchange Commission.

                                    ###